FIGURE

Fig. 6

ID

ZDB-FIG-240529-33

Publication

Chen et al., 2024 - Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

The integrated analysis of transcriptomic and metabolomic profiles following wedelolactone (WEL) and demethylwedelolactone (DWEL) treatment. (A) Single-sample gene set enrichment analysis (ssGSEA) of the key metabolic pathway across each sample. (B) Gene set enrichment analysis (GSEA) of steroid biosynthesis and fatty acid elongation in WEL and DWEL treatment group vs. non-alcoholic fatty liver disease (NAFLD) group. (C) The biological processes of steroid synthesis, fatty acid metabolism, and glutathione metabolism, and the crucial genes involved. (D) The relative mRNA levels of genes in essential metabolic pathways determined by quantitative real-time PCR (qRT-PCR). Data are presented as mean � standard deviation (SD) (n = 10). ?P < 0.05, ???P < 0.001, ns: no significance. NES: normalized enrichment score; FDR: false discovery rate; TAA: thioacetamide; farnesyl-PP: farnesyl pyrophosphate.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J Pharm Anal